Loading...
01/11 05:00
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights significant challenges: a GAAP net loss of $19.4 million, high cash burn, and competitive pressures. Despite initial revenue from product launches, financial sustainability is a concern. The Q&A reveals uncertainties in strategic partnerships and trial outcomes. These factors, coupled with increased costs and competitive risks, suggest a negative sentiment. Without strong guidance or partnerships, the stock is likely to face downward pressure.
Total Revenue $86,000 in Q3 2025. This marks the initial revenues comprised of both nPulse capital and Vybrance disposable sales as the company initiated its limited market release.
Total GAAP Costs and Expenses $20.5 million in Q3 2025, an increase of $6.8 million compared to $13.7 million in the prior year period. The increase was primarily driven by expenses related to the expanding organization to support advancement of nsPFA device clinical trials and commercialization, along with noncash stock-based compensation.
Noncash Stock-Based Compensation $5.6 million in Q3 2025 compared to $3 million in the prior year period. This accounted for 38% of the year-over-year increase in costs and expenses.
Total Non-GAAP Costs and Expenses $14.6 million in Q3 2025, an increase of $4.2 million compared to $10.4 million in the prior year period.
GAAP Net Loss $19.4 million in Q3 2025 compared to $12.7 million in the prior year period. The increase reflects higher costs and expenses.
Non-GAAP Net Loss $13.5 million in Q3 2025 compared to $9.4 million in the prior year period.
Cash and Cash Equivalents $95.2 million as of September 30, 2025, compared to $79 million as of September 30, 2024. This represents a decrease of $11.1 million versus Q2 of 2025.
Cash Used in Operating Activities $13 million in Q3 2025 compared to $9 million in the prior year period and $12.8 million in Q2 of 2025. The increase was due to continued expense management and deliberate resource expansion.
nPulse Vybrance percutaneous electrode system: New product and technology naming introduced. The proprietary nanosecond PFA platform is now called nPulse Technology, and the percutaneous electrode is named Vybrance. Over 200 patients treated in pilot programs and commercial procedures. Positive outcomes and growing utilization reported. Initial revenues recognized in Q3 2025.
nPulse cardiac surgery system: Received FDA investigational device exemption approval for atrial fibrillation treatment. First patient enrolled and treated in IDE study. European feasibility studies progressing with 44 patients treated. Promising initial data presented at the European Association for Cardiothoracic Surgery Meeting.
nPulse 360 Catheter: Designed for atrial fibrillation ablation. European feasibility study enrolled 150 patients. IDE submission progressing with FDA, study expected to commence in Q1 2026. New safety and efficacy data anticipated in Q1 2026.
Soft tissue ablation market: Vybrance system targets benign thyroid nodule treatment. Positive patient flow and insurance claims processing observed. Economic benefits highlighted compared to traditional thyroidectomy.
Cardiac ablation market: nPulse cardiac surgical system and 360 Catheter aim to address atrial fibrillation treatment. European feasibility studies and IDE submissions progressing. Potential for strategic partnerships in electrophysiology.
Commercialization efforts: Initial revenues of $86,000 recognized in Q3 2025. Focus on pilot programs, training, and market access. Expansion into new geographies planned after achieving desired utilization levels.
Regulatory progress: FDA IDE approval for nPulse cardiac surgery system. Ongoing IDE submission for nPulse 360 Catheter. European feasibility studies advancing for both devices.
Strategic focus: Advancing nPulse technology for soft tissue and cardiac ablation. Emphasis on clinical validation, market access, and patient outcomes. Exploring strategic partnerships in electrophysiology.
Regulatory hurdles: The company is engaged in regulatory processes for its devices, including FDA investigational device exemption (IDE) approvals and European feasibility studies. Delays or challenges in obtaining regulatory approvals could impact the timeline for product launches and market penetration.
Market adoption and utilization: The company is in the early stages of launching its nPulse Vybrance system and is focused on driving procedure counts and physician training. Slow adoption or lack of physician interest could hinder commercial success.
Reimbursement challenges: While there is a positive trend in insurance claims being processed, the company is still working to confirm market access for commercial reimbursement. Lack of payer support could limit patient access and procedural growth.
Financial sustainability: The company reported a GAAP net loss of $19.4 million for Q3 2025 and is using significant cash for operating activities. Sustained losses and high cash burn could impact long-term financial viability.
Competitive pressures: The company operates in a highly competitive market for medical devices, particularly in the areas of soft tissue ablation and atrial fibrillation treatment. Competitors with established market presence could pose challenges.
Clinical trial risks: The company is conducting multiple clinical studies, including the PRECISE-BTN study and IDE studies for cardiac devices. Delays, adverse outcomes, or failure to meet endpoints could impact regulatory approvals and market confidence.
Supply chain and operational risks: The company is expanding its organization and operations to support commercialization and clinical trials. Any disruptions in the supply chain or operational inefficiencies could delay product availability and increase costs.
Revenue Growth: Looking ahead, the company expects disposables and nPulse system sales to grow along with overall procedure acceptance. A large portion of procedures are currently being completed under the pilot program or as part of the PRECISE study, which are not included in revenue totals.
Commercial Expansion: The company plans to maintain consistent commercial headcount in Q4, focusing on expanding accounts in existing large metropolitan geographies. Once initial accounts achieve desired utilization levels, headcount will expand, and new geographies will be launched.
Clinical Studies and Regulatory Progress: The PRECISE-BTN study is progressing with more than 40% enrollment to date and is expected to complete enrollment in Q1 2026. Results will be reported in the next quarterly update. The IDE pivotal study for the nPulse surgical ablation clamp has been approved by the FDA, with the first patient enrolled and treated. The company plans to expand into additional sites by the end of the year and into Q1 2026. The IDE study for the nPulse 360 Catheter is expected to commence in Q1 2026 after resolving remaining open items with the FDA.
Market Trends and Adoption: The company is encouraged by positive trends in insurance claims being processed and paid, supporting the clinical value of procedures. The perceived safety benefits and economic arguments for the Vybrance procedure are expected to drive adoption and utilization. Long-term follow-up evaluations and additional data publications will play a critical role in scaling commercial efforts.
Strategic Partnerships: The company is exploring potential collaborations with established leaders in electrophysiology to accelerate growth and achieve significant market penetration. Updates on partnership progress will be shared as appropriate.
The selected topic was not discussed during the call.
The earnings call highlights significant challenges: a GAAP net loss of $19.4 million, high cash burn, and competitive pressures. Despite initial revenue from product launches, financial sustainability is a concern. The Q&A reveals uncertainties in strategic partnerships and trial outcomes. These factors, coupled with increased costs and competitive risks, suggest a negative sentiment. Without strong guidance or partnerships, the stock is likely to face downward pressure.
The earnings call highlights strong strategic developments, including a new partnership in cardiac ablation and compatibility with major mapping systems. Despite increased expenses and net losses, the company maintains a solid cash position, indicating disciplined financial management. The positive aspects, such as the partnership and product compatibility, outweigh the negatives, suggesting a likely positive stock reaction.
The earnings call presents a mixed picture. Strong clinical progress and FDA clearances are positive, but the financials show widening losses and increased expenses, which are concerning. The market strategy shows promise, but regulatory and competitive risks remain. The Q&A section didn't reveal additional negative sentiment. Given the balance of positive clinical developments and financial concerns, the stock price is likely to remain stable in the near term, resulting in a neutral prediction.
The earnings call presents a mixed picture. While there are positive developments such as FDA clearances, strengthened financials through warrant exercises, and strategic market initiatives, there are also significant risks. These include competitive pressures, regulatory challenges, and increased financial losses. The absence of guidance and the acknowledgment of potential supply chain and economic risks further contribute to a cautious outlook. As a result, the stock price is likely to remain stable in the short term, with movements within a neutral range of -2% to 2%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
